InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) saw a large decline in short interest in the month of May. As of May 29th, there was short interest totaling 1,202,243 shares, a decline of 56.6% from the May 14th total of 2,773,329 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
InnoCare Pharma Stock Performance
Shares of INCPF stock remained flat at $1.55 during midday trading on Friday. The company’s fifty day moving average price is $1.55 and its 200-day moving average price is $1.79. InnoCare Pharma has a 52 week low of $1.55 and a 52 week high of $2.31.
Wall Street Analyst Weigh In
Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, InnoCare Pharma presently has an average rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Featured Articles
- Five stocks we like better than InnoCare Pharma
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
